FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk
Agency awards $22m to support 15 clinical trials and approximately $10m for six natural history studies in rare diseases. FDA Commissioner Gottlieb highlights the program as a way for the agency to help de-risk clinical development.
You may also be interested in...
US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.